Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancer
NEW YORK — Rucaparib (Rubraca) turned in mixed results for survival outcomes in patients with recurrent ovarian carcinoma, according to an ARIEL3 trial update. There was a benefit for progression-free survival (PFS), as treatment with the PARP inhibitor was tied to longer time-to-second disease progression (PFS2) in patients with BRCA-mutated disease (26.1 months versus 18.4 […]
CDC Warns of Severe Monkeypox in People With HIV, the Immunocompromised
Be alert for potentially severe manifestations of monkeypox in patients who are immunocompromised or co-infected with HIV, the CDC told healthcare workers on Thursday. “People who are immunocompromised due to HIV or other conditions are at higher risk for severe manifestations of monkeypox than people who are immunocompetent,” the agency said in a health advisory […]
Low-Dose Cariprazine for MDD Tied to Anxiety Reduction
NEW ORLEANS — Low-dose cariprazine (Vraylar) was associated with reductions in anxiety for patients with major depressive disorder (MDD), and the potential adjunctive therapy for this population also demonstrated improvements across most individual symptoms of depression, according to two post hoc analyses of a phase III trial. When combined with an antidepressant for MDD patients […]
U.S. Task Force Recommends All Adults Under 65 Be Screened For Anxiety
A U.S. advisory group of medical experts recommended all patients under the age of 65 be screened for anxiety for the first time, a major effort that hopes to expand mental health care as the toll of the COVID-19 pandemic continues to climb. The group, the U.S. Preventative Services Task Force, released its draft recommendation […]
PCI vs CABG: Does Age Inform Choice for Left Main Coronary Artery Disease?
BOSTON — Adding fuel to the controversy of revascularization for left main disease, patients had better survival after coronary artery bypass grafting (CABG) surgery than percutaneous coronary intervention (PCI) in an all-comers nationwide registry study. The incidence of all-cause mortality stayed greater up to 7 years after PCI versus CABG (adjusted HR 1.59, 95% CI […]
Clinical Decision Tool Cuts Inappropriate BMA Therapy in Prostate Cancer
SAN DIEGO — An algorithm-based decision tool eliminated inappropriate prescribing of bone-modifying agents (BMA) in patients with advanced prostate cancer, according to a VA-based study. Prior to implementing the tool, inappropriate BMA prescribing was found in more than 50% of cases of men with metastatic sensitive-resistant prostate cancer (mCSPC) without bone metastases at the George […]
Is TAVR in Small Aortic Annuli Better With Self-Expanding Valves?
BOSTON — Transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli had better hemodynamic results with a self-expandable than a balloon-expandable valve, with suggestion of better clinical outcomes too, in the France-TAVI registry. Mean gradient was significantly lower with self-expanding Medtronic CoreValve Evolut Pro or R devices at the end of the procedure […]
Is it really healthy to restrict protein intake for kidney transplant recipients? Study suggests that sufficient protein intake is necessary to prevent sarcopenia after kidney transplantation
Conventional wisdom holds that low protein intake is essential for kidney disease patients. However, scientists from Osaka Metropolitan University demonstrated that it might not always be the case with their recent study on the relationship between protein intake and skeletal muscle mass in kidney transplant recipients. Their findings were published in Clinical Nutrition. Chronic kidney […]
Want Us to Find the Fountain of Youth? Give Us Endpoints, Scientists Say
WASHINGTON — Better surrogate endpoints are needed to help patients benefit from anti-aging therapies, experts told a House committee Thursday. “It would be important to develop different metrics of measuring success,” said Steve Horvath, PhD, principal investigator at Altos Labs, a San Francisco-based biotechnology company focused on cellular rejuvenation programming. “Imagine that you have a […]
Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer
PARIS — Nearly two-thirds of patients with untreated cisplatin-ineligible advanced urothelial cancer responded to an antibody-drug conjugate (ADC) and immunotherapy, a small randomized study showed. Overall, 49 of 76 patients responded to frontline enfortumab vedotin (EV; Padcev) and pembrolizumab (Keytruda), including eight complete responses. An additional 17 patients had stable disease, resulting in a clinical […]